|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
SaturdaySchering: CRA-028129
"Schering's interest is in "autoimmune disease, of which multiple sclerosis is an important part," Speechly said. It plans to develop CRA-028129 initially for multiple sclerosis, adding to an existing Phase III program exploring high-dose interferon beta-1b and a Phase II program for alemtuzumab in MS."
|